

A multidisciplinary conversation on the stories of women with Fabry disease

Chair

Dawn A. Laney, MS, CGC, CCRC, Emory University School of Medicine, Atlanta, GA, USA

Faculty

Robert J. Hopkin, MD, FACMG, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA

Anjay Rastogi, MD, PhD, UCLA David Geffen School of Medicine, Los Angeles, CA, USA

Release date: May 31, 2022

Expiration date: May 31, 2023

Estimated time to completion: 1.5 hour

Available CME credits: 1.5 AMA PRA Category 1 Credit(s)[™]

Activity description

This webcast will provide an interactive, patient-focused learning experience on the challenges experienced by females with Fabry disease (FD), who have long been considered solely as "carriers of the disease". You can learn about patients' personal experiences and be involved in a lively exchange between leading experts and the audience. The clinical journey from diagnosis to treatment will be analyzed, and best practices for multidisciplinary management addressing the specific needs of females with FD will be discussed. Furthermore, the experts will review the latest clinical evidence on novel and emerging therapies and provide perspectives on treatment strategies and future clinical trial design.

Target audience

This activity is intended for medical and clinical geneticists, metabolic geneticists, genetic counselors, and other healthcare professionals providing comprehensive diagnostic and therapeutic management and counseling services for patients with or at risk for Fabry disease.

Educational objectives

After completing this activity, the participant should be better able to:

- **Recognize** the importance of the inclusion of females in clinical trials of FD and of addressing their specific needs in the trial design
- **Describe** the symptoms at onset of FD in heterozygous females with the disease
- **Explain** how early initiation of FD-specific treatment benefits heterozygous females

- **Utilize** methods for optimizing treatment strategies for females with FD, including referral, early initiation, and follow-up

Joint accreditation statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Ology Medical Education. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.



JOINTLY ACCREDITED PROVIDER™
INTERPROFESSIONAL CONTINUING EDUCATION

Physician continuing medical education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.5 *AMA PRA Category 1 Credit(s)*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Method of participation and request for credit

There are no fees for participating in, and receiving CME/CE credit for, this activity.

In order to claim credit, participants must complete the following procedures during the period May 31, 2022, through May 31, 2023:

1. Read the educational objectives, accreditation information, and faculty disclosures
2. View the expert discussion
3. Take the post-activity test and complete the evaluation
4. Indicate the number of credits earned and download the certificate of CME credit

Disclosure of conflicts of interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Faculty	Relationship identified with:
Dawn A. Laney, MS, CGC, CCRC	Consulting fees from Amicus Therapeutics; Sanofi Genzyme, Spark Therapeutics, Inc. Ownership interest (less than 5%) in ThinkGenetic.
Robert J. Hopkin, MD, FACMG	Consulting fees from Alexion Pharmaceuticals Inc., Amicus Therapeutics, AVROBIO, Inc., Chiesi USA, Inc., Sangamo Therapeutics, Inc., Sanofi Genzyme, Takeda. Advisory arrangements with Alexion Pharmaceuticals Inc., Amicus Therapeutics, Sanofi Genzyme. Speakers bureau member for Alexion Pharmaceuticals Inc., Sanofi Genzyme. Grants/contracts research from Alexion Pharmaceuticals Inc., Amicus Therapeutics, Idorsia Pharmaceuticals Ltd, Protalix BioTherapeutics, Inc., Sanofi Genzyme, Takeda.
Anjay Rastogi, MD, PhD	Consulting fees from Adept Field Solutions, Spire Learning, Sanofi.

Planners and managers

The PIM planners and managers have nothing to disclose. The Ology Medical Education planners and managers have nothing to disclose.

Provider information

Jointly provided by Postgraduate Institute for Medicine and Ology Medical Education.



Financial support

This activity is supported by an independent educational grant from Amicus Therapeutics Inc.

Disclosure of unlabeled use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing

information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities. The course materials are for educational purposes only and should not be reproduced or distributed in any way. If you wish to reproduce, store in a retrieval system, transmit in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, any part of the material presented, you will need to obtain all the necessary permissions by writing to the publisher, the original author, or any other current copyright owner.

Contact information for questions about the activity

Elena Knoche, Senior Medical Communications Manager
info@ologyeducation.org, www.ologyeducation.org

Chantel Crowl, Program Manager
inquiries@pimed.com, www.pimed.com

System requirements

Ology Education requires a modern web browser (Google Chrome, Mozilla Firefox, Apple Safari, Microsoft Edge). Certain educational activities may require a PDF reader such as Adobe Acrobat Reader to view.

Policy on Privacy and Confidentiality

Please see final activity for the policy on privacy and confidentiality that relates to this internet activity.

Media

Internet